8V4X image
Entry Detail
PDB ID:
8V4X
Title:
Structure of MALT1 in complex with an allosteric inhibitor
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2023-11-29
Release Date:
2024-05-01
Method Details:
Experimental Method:
Resolution:
2.49 Å
R-Value Free:
0.28
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Mucosa-associated lymphoid tissue lymphoma translocation protein 1
Chain IDs:A, B, C, D, E, F
Chain Length:387
Number of Molecules:6
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Inhibitor peptide
Chain IDs:G, H, I, J, K, L
Chain Length:6
Number of Molecules:6
Biological Source:synthetic construct
Ligand Molecules
Peptide-like Molecules
PRD_001076
Primary Citation

Abstact

The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme that is constitutively activated by stimulation of the B-cell receptor or gain-of-function mutations in upstream components of the signaling pathway, making it an attractive therapeutic target. We discovered a novel small-molecule inhibitor, ABBV-MALT1, that potently shuts down B-cell signaling selectively in ABC-DLBCL preclinical models leading to potent cell growth and xenograft inhibition. We also identified a rational combination partner for ABBV-MALT1 in the BCL2 inhibitor, venetoclax, which when combined significantly synergizes to elicit deep and durable responses in preclinical models. This work highlights the potential of ABBV-MALT1 monotherapy and combination with venetoclax as effective treatment options for patients with ABC-DLBCL.

Legend

Protein

Chemical

Disease

Primary Citation of related structures